E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
We want to determine the optimal loading dose of intravenous Acetaminophen in neonates of different gestational age subgroups.
To this effect a loading dose of 10mg/kg, 15mg/kg or 20mg/kg Acetaminophen will be administered to neonates with a gestational age of 24 –42 weeks when they need to endure a mild painful procedure. All concentration-time profiles will be used in a pharmacokinetic analysis of acetaminophen using a non-linear mixed effects model (NONMEM).
|
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Primary Objective: Pharmacokinetic properties of Acetaminophen in neonates: Safety and Efficacy Profile: Determine optimal loading dose of Acetaminophen in different age-subgroup. Safety outcome parameters are: - acetaminophen serum levels, - acetaminophen metabolite levels in urine samples - renal function - hepatotoxicity (determine NAPQ1levels as indicator). Pharmacodynamic properties of Acetaminophen in neonates: Comfortneo score and PIPP as pain assessment tools used in the different dose regimens of acetaminophen compared to the control group receiving sucrose. |
|
E.2.2 | Secondary objectives of the trial |
Secondary Objective(s): Registration and/or drug interaction: - Influence of drugs metabolised by cytochrome P-450 on serum levels of acetaminophen: indomethacin; - Influence of acetaminophen on indomethacin-treatment of PDA closure; - Influence of acetaminophen on bilirubin glucuronidation
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Inclusion criteria · neonates (in- and outborn) with a gestational age of 24-42 weeks · admission within the first 24 hours of life · indwelling arterial catheter · painful procedures within the first week of life · Informed consent of the parents or legal guardian
|
|
E.4 | Principal exclusion criteria |
4.3. Exclusion criteria · major congenital anomalies · intraventriculair haemorrhage > grade 2 · neuromuscular blockers · absence of an indwelling catheter · use of morphine, midazolam or sucrose at start of the study
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
1 Pharmacokinetic properties of acetaminophen in neonates: safety and efficacy profile Determine optimal loading dose of acetaminophen in different age subgroups Safety outcome parameters are: Acetaminophen serum levels Acetaminophen metabolite levels in urine samples renal function hepatotoxicity( determine NAPQ1 levels as indicator)
2 Pharmacodynamic properties: ComfortNeo score and PIPP as pain assessment tools used in different dose regimens of acetaminophen compared to control groups receiving sucrose
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.3.1 | Comparator description |
IMP is compared with the standard treatment with oral sucrose |
|
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |